Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2007 1
2014 2
2015 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.
Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, Matthews J, Norton AJ, Amess JA, Lister TA. Johnson PW, et al. J Clin Oncol. 1995 Jan;13(1):140-7. doi: 10.1200/JCO.1995.13.1.140. J Clin Oncol. 1995. PMID: 7799014
PURPOSE: To examine outcome of treatment for patients with recurrent follicular lymphoma. PATIENTS AND METHODS: Two hundred twelve newly diagnosed follicular lymphoma patients were studied. ...The median duration of second remission was 13 months, (v 31 month …
PURPOSE: To examine outcome of treatment for patients with recurrent follicular lymphoma. PATIENTS AND METHODS: Two hun …
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, Orsucci L, Liberati M, Vallisa D, Brugiatelli M; Italian Lymphoma Study Group. Sacchi S, et al. Cancer. 2007 Jul 1;110(1):121-8. doi: 10.1002/cncr.22740. Cancer. 2007. PMID: 17503433 Free article. Clinical Trial.
BACKGROUND: The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine and cyclophosphamide in patients with recurrent follicular lymphoma (FL). METHODS: This study was a noncomparative, mult …
BACKGROUND: The current study was conducted to asses the safety profile and clinical activity of rituximab in combination with fludarabine a …
Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
Berinstein NL, Bhella S, Pennell NM, Cheung MC, Imrie KR, Spaner DE, Milliken V, Zhang L, Hewitt K, Boudreau A, Reis MD, Chesney A, Good D, Ghorab Z, Hicks LK, Piliotis E, Buckstein R. Berinstein NL, et al. Ann Hematol. 2015 May;94(5):813-23. doi: 10.1007/s00277-014-2288-5. Epub 2015 Jan 8. Ann Hematol. 2015. PMID: 25567231 Clinical Trial.
Three sequential phase II trials were conducted with different immunotherapy approaches to enhance the outcome of autologous transplant (high-dose therapy and autologous stem cell transplantation (HDT/ASCT)) for recurrent follicular lymphoma. Seventy-three pa …
Three sequential phase II trials were conducted with different immunotherapy approaches to enhance the outcome of autologous transplant (hig …
Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience.
Helbig G, Krawczyk-Kulis M, Kopinska A, Liwoch R, Kyrcz-Krzemien S. Helbig G, et al. Med Oncol. 2014 Dec;31(12):310. doi: 10.1007/s12032-014-0310-3. Epub 2014 Nov 6. Med Oncol. 2014. PMID: 25373321 Free PMC article. Clinical Trial.
Autologous hematopoietic stem cell transplantation (AHSCT) is a treatment option for relapsed and recurrent follicular lymphoma (R/R FL); however, its value in the rituximab era remains to be elucidated. ...There was no significant difference in OS and PFS in …
Autologous hematopoietic stem cell transplantation (AHSCT) is a treatment option for relapsed and recurrent follicular lymp …
Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report.
Zhong N, Ma Q, Gong S, Shi Y, Zhao L, Wang D, Zhou H, Liu N, Ye Y, Wang J, Liu L, Guo Z. Zhong N, et al. Int Immunopharmacol. 2024 Jun 15;134:112174. doi: 10.1016/j.intimp.2024.112174. Epub 2024 May 3. Int Immunopharmacol. 2024. PMID: 38703571 Free article.
This may be the first case report of RV preparation of novel CD19 CAR-T cells for direct treatment of recurrent follicular lymphoma. We will observe its long-term efficacy and conduct trials in more patients in the future....
This may be the first case report of RV preparation of novel CD19 CAR-T cells for direct treatment of recurrent follicular …
Dynamic metabolic changes during the first 3 months after 90Y-ibritumomab tiuxetan radioimmunotherapy.
Takahashi M, Momose T, Koyama K, Ichikawa M, Kurokawa M, Ohtomo K. Takahashi M, et al. ScientificWorldJournal. 2014;2014:368947. doi: 10.1155/2014/368947. Epub 2014 Jun 19. ScientificWorldJournal. 2014. PMID: 25050390 Free PMC article.
OBJECTIVE: To elucidate the time course of tumor metabolism during the first 3 months after (90)Y-ibritumomab tiuxetan radioimmunotherapy (RIT) in patients with refractory malignant lymphoma. MATERIALS AND METHODS: Seven patients with recurrent follicular lymphom …
OBJECTIVE: To elucidate the time course of tumor metabolism during the first 3 months after (90)Y-ibritumomab tiuxetan radioimmunotherapy (R …